SANOFI-AVENTIS (EPA:SAN) ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
Transparency directive : regulatory news
24/02/2023 17:16